In this randomized, placebo-controlled phase 3 clinical trial, the authors assess efficacy, immunogenicity, and safety of the inactivated SARS-CoV-2 vaccine CoronaVac in children and adolescents aged 6 months to 17 years. The study was carried out in Chile, South Africa, Malaysia, and the Philippines, and coincided with the emergence of the Omicron variant.
- Qianqian Xin
- Kaiqin Wang
- Gang Zeng
